Zaleplon - Meda

Drug Profile

Zaleplon - Meda

Alternative Names: CL 284846; L 846; LJC 10846; Sonata; Zerene

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Meda; Wyeth
  • Class Acetamides; Hypnosedatives; Pyrimidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 01 Mar 2011 King Pharmaceuticals has been acquired and merged into Pfizer
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top